Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Look: Discussing the recent FDA approval of Cobenfy (KarXT), an oral antipsychotic developed by BMS and Karuna for the treatment of schizophrenia.

Ticker(s): BMY, KRTX

Who's the expert?

Institution: Lifetime Insight

Private practice psychologist
Manages 100 patients with bipolar disorders

Interview Goal

to discuss the current treatment landscape and the potential of Cobenfy (KarXT), an oral antipsychotic which was recently approved by the FDA for the treatment of schizophrenia.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here To Join
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Call Date: Nov 22, 2024
Call Time: 03:00 PM EST

Wall Street Time

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here To Join
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.